• 1
    Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood. 1996; 15: 12071210.
  • 2
    Nakamura S, Suchi T, Koshikawa T, et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol. 1995; 19: 284296.
  • 3
    Kobashi Y, Nakamura S, Sasajima Y, et al. Inconsistent association of Epstein-Barr virus with CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Histopathology. 1996; 28: 111120.
  • 4
    Chan JKC, Jaffe ES, Ralfkiaer E. Blastic NK-cell lymphoma. In: JaffeES, HarrisNL, SteinH, VardimanJW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001: 214215.
  • 5
    Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996; 20: 103111.
  • 6
    Oshimi K. Leukemia and lymphoma of natural killer lineage cells. Int J Hematol. 2003; 78: 1823.
  • 7
    Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res. 1999; 23: 615624.
  • 8
    Reimer P, Rudiger T, Kraemer D, et al. What is CD4+ CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003; 32: 637646.
  • 9
    Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004; 15: 10971108.
  • 10
    Pirruccello SJ, Bicak MS, Gordon BG, Gajl-Peczalska K, Gnarra DJ, Coccia PF. Acute lymphoblastic leukemia of NK-cell lineage: response to IL-2. Leuk Res. 1989; 13: 735743.
  • 11
    Ichikawa M, Kawai H, Komiyama A, et al. Functional p75 interleukin-2 receptor expression on the fresh blast cells in childhood acute lymphoblastic leukemia with natural killer cell properties. Am J Hematol. 1991; 36: 259264.
  • 12
    Brody JP, Allen S, Schulman P, et al. Acute agranular CD4-positive natural killer cell leukemia. Cancer. 1994; 75: 24742483.
  • 13
    Gardiner CM, Reen DJ, O'Meara A. Recognition of unusual presentation of natural killer cell leukemia. Am J Hematol. 1995; 50: 133139.
  • 14
    Nakamura F, Tatsumi E, Kawano S, et al. Acute lymphoblastic leukemia/lymphoblastic lymphoma of natural killer (NK) lineage: quest for another NK-lineage neoplasm. Blood. 1997; 89: 46654666.
  • 15
    Shinoda K, Muraki T, Yano M, Yamada T, Takao A. Infant leukemia suggestive of natural killer cell precursor origin followed an unusual clinical course. Acta Haematol. 2000; 104: 202206.
  • 16
    Alvarez-Larran A, Villamor N, Hernandez-Boluda JC, et al. Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia. Clin Lymphoma. 2001; 2: 178182.
  • 17
    Falcao RP, Garcia AB, Marques MG, et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk Res. 2002; 26: 803807.
  • 18
    DuBois SG, Etzell JE, Matthay KK, Robbins E, Banerjee A. Pediatric acute blastic natural killer cell leukemia. Leuk Lymphoma. 2002; 43: 901906.
  • 19
    Weiss LM, Bindl JM, Picozzi VJ, Link MP, Warnke RA. Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood. 1986; 67: 474478.
  • 20
    Maitra A, McKenna RW, Weinberg AG, Schneider NR, Kroft SH. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol. 2001; 115: 868875.
  • 21
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 38353849.
  • 22
    Bayerl MG, Rakozy CK, Mohamed AN, et al. Blastic natural killer cell lymphoma/leukemia: a report of seven cases. Am J Clin Pathol. 2002; 117: 4150.
  • 23
    Savoia P, Fierro MT, Novelli M, et al. CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol. 1997; 137: 966971.
  • 24
    Ko YH, Kim SH, Ree HJ. Blastic NK-cell lymphoma expressing terminal deoxynucleotidyl transferase with Homer-Wright type pseudorosettes formation. Histopathology. 1998; 33: 547553.
  • 25
    Petrella T, Dalac S, Maynadie M, et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol. 1999; 23: 137146.
  • 26
    Nagatani T, Okazawa H, Kambara T, et al. Cutaneous monomorphous CD4− and CD56-positive large-cell lymphoma. Dermatology. 2000; 200: 202208.
  • 27
    Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001; 97: 32103217.
  • 28
    Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4+ CD56+ malignancies. Blood. 2002; 99: 15561563.
  • 29
    Petrella T, Comeau MR, Maynadie M, et al. ‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002; 26: 852862.
  • 30
    Oshimi K, Kawa K, Nakamura S, et al. A nationwide survey of NK-cell neoplasms in Japan[abstrat]. Blood. 2003; 102: 413a.
  • 31
    Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer (NK)-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004; 18: 763770.
  • 32
    Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null cell phenotype. Blood. 2000; 96: 29933000.
  • 33
    Berg EL, Yoshino T, Rott LS, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med. 1991; 174: 14611466.
  • 34
    Yoshino T, Nakamura S, Suzumiya J, et al. Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma. Br J Haematol. 2002; 118: 482487.
  • 35
    Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/NK cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997; 90: 24172428.
  • 36
    Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003; 97: 610627.
  • 37
    Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004; 28: 719735.
  • 38
    Karube K, Ohshima K, Tsuchiya T, et al. Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol. 2003; 27: 13661374.
  • 39
    Khoury JD, Medeiros LJ, Manning JT, Sulak LE, Bueso-Ramos C, Jones D. CD56+ TdT+ blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002; 94: 24012408.
  • 40
    Suzuki R, Murata M, Kami M, et al. Prognostic significance of CD7+ CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol. 2003; 77: 482489.
  • 41
    Tamura H, Ogata K, Mori S, et al. Lymphoblastic lymphoma of natural killer cell origin, presenting as pancreatic tumour. Histopathology. 1998; 32: 508511.
  • 42
    Kameoka J, Ichinohasama R, Tanaka M, et al. A cutaneous agranular CD2− CD4+ CD56+ “lymphoma”: report of two cases and review of the literature. Am J Clin Pathol. 1998; 110: 478488.
  • 43
    Kato N, Yasukawa K, Onozuka T, Kikuta H. Nasal and nasal-type T/NK-cell lymphoma with cutaneous involvement. J Am Acad Dermatol. 1999; 40: 850856.
  • 44
    Kojima H, Mukai HY, Shinagawa A, et al. Clinicopathological analyses of 5 Japanese patients with CD56+ primary cutaneous lymphomas. Int J Hematol. 2000; 72: 477483.
  • 45
    Yamada O, Ichikawa M, Okamoto T, et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol. 2001; 113: 153160.
  • 46
    Kinney MC. The role of morphologic features, phenotype, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasm. Am J Clin Pathol. 1999; 111( Suppl 1): S104S108.
  • 47
    O'Doherty U, Steinman RM, Peng M, et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med. 1993; 178: 10671076.
  • 48
    Sotzik F, Rosenberg Y, Boyd AW, et al. Assessment of CD4 expression by early T precursor cells and by dendritic cells in the human thymus. J Immunol. 1994; 152: 33703377.
  • 49
    Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA. 1997; 94: 1255112556.
  • 50
    Vandenabeele S, Hochrein H, Mavaddat N, Winkel K, Shortman K. Human thymus contains 2 distinct dendritic cell populations. Blood. 2001; 97: 17331741.
  • 51
    Momoi A, Toba K, Kawai K, et al. Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases. Leuk Res. 2002; 26: 693698.
  • 52
    Petrella T. Author's reply for Facchetti F, Vermi W, Santoro A, Vergoni F, Chilosi M, Doglioni C. Neoplasms derived from plasmacytoid monocytes/interferon-producing cells: variability of CD56 and granzyme B expression. Am J Surg Pathol. 2003; 27: 14921493.
  • 53
    Sato N, Caux C, Kitamura T, et al. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood. 1993; 82: 752761.
  • 54
    Miyajima A, Mui AL, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood. 1993; 82: 19601974.
  • 55
    Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004; 122: 307313.
  • 56
    Morabito F, Prasthofer EF, Pullen DJ, et al. Analysis of surface antigen profile, TdT expression, and T cell receptor gene rearrangement for maturational staging of leukemic T cells: a Pediatric Oncology Group study. Leukemia. 1987; 1: 514517.
  • 57
    Drexler HG, Sperling C, Ludwig WD. Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia. Leukemia. 1993; 7: 11421150.
  • 58
    Drénou B, Lamy T, Amiot L, et al. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997; 89: 29662974.
  • 59
    Suminoe A, Matsuzaki A, Takada H, et al. An infant with precursor natural killer (NK) cell leukemia successfully treated with an unrelated cord blood transplantation. Leuk Lymphoma. 2000; 39: 641646.
  • 60
    Yoshimasu T, Manabe A, Tanaka R, et al. Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. Bone Marrow Transplant. 2002; 30: 4144.
  • 61
    Hyakuna N, Toguchi S, Higa T, et al. Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2004; 42: 631634.